Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,928 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal biomarkers in amyotrophic lateral sclerosis.
Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH Jr, Ladha SS, Lacomis D, Harris JM, Scearce-Levie K, Ho C, Bowser R, Berry JD. Huang F, et al. Among authors: ho c. Ann Clin Transl Neurol. 2020 Jul;7(7):1103-1116. doi: 10.1002/acn3.51078. Epub 2020 Jun 9. Ann Clin Transl Neurol. 2020. PMID: 32515902 Free PMC article.
DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers.
Grievink HW, Heuberger JAAC, Huang F, Chaudhary R, Birkhoff WAJ, Tonn GR, Mosesova S, Erickson R, Moerland M, Haddick PCG, Scearce-Levie K, Ho C, Groeneveld GJ. Grievink HW, et al. Among authors: ho c. Clin Pharmacol Ther. 2020 Feb;107(2):406-414. doi: 10.1002/cpt.1615. Epub 2019 Sep 25. Clin Pharmacol Ther. 2020. PMID: 31437302 Clinical Trial.
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, Tong V, Erickson R, Zhu Y, Scearce-Levie K, Hsiao-Nakamoto J, Tang X, Chang M, Fox BM, Estrada AA, Pomponio RJ, Alonso-Alonso M, Zilberstein M, Atassi N, Troyer MD, Ho C. Vissers MFJM, et al. Among authors: ho c. Clin Transl Sci. 2022 Aug;15(8):2010-2023. doi: 10.1111/cts.13317. Epub 2022 Jun 1. Clin Transl Sci. 2022. PMID: 35649245 Free PMC article. Clinical Trial.
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D, Ellenbogen A, Goodman I, Siderowf A, Aldred J, Omidvar O, Masoud ST, Davis SS, Arguello A, Estrada AA, de Vicente J, Sweeney ZK, Astarita G, Borin MT, Wong BK, Wong H, Nguyen H, Scearce-Levie K, Ho C, Troyer MD. Jennings D, et al. Among authors: ho c. Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8. Sci Transl Med. 2022. PMID: 35675433
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
Young CB, Winer JR, Younes K, Cody KA, Betthauser TJ, Johnson SC, Schultz A, Sperling RA, Greicius MD, Cobos I, Poston KL, Mormino EC; Alzheimer’s Disease Neuroimaging Initiative and the Harvard Aging Brain Study. Young CB, et al. JAMA Neurol. 2022 Jun 1;79(6):592-603. doi: 10.1001/jamaneurol.2022.0676. JAMA Neurol. 2022. PMID: 35435938 Free PMC article.
Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation.
Kosik KS, Muñoz C, Lopez L, Arcila ML, García G, Madrigal L, Moreno S, Ríos Romenets S, Lopez H, Gutierrez M, Langbaum JB, Cho W, Suliman S, Tariot PN, Ho C, Reiman EM, Lopera F. Kosik KS, et al. Among authors: ho c. Neurology. 2015 Jan 13;84(2):206-8. doi: 10.1212/WNL.0000000000001130. Epub 2014 Dec 3. Neurology. 2015. PMID: 25471389 Free PMC article. No abstract available.
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
Bocancea DI, Svenningsson AL, van Loenhoud AC, Groot C, Barkhof F, Strandberg O, Smith R; Alzheimer’s Disease Neuroimaging Initiative; La Joie R, Rosen HJ, Pontecorvo MJ, Rabinovici GD, van der Flier WM, Hansson O, Ossenkoppele R. Bocancea DI, et al. Brain. 2023 Sep 1;146(9):3719-3734. doi: 10.1093/brain/awad100. Brain. 2023. PMID: 36967222 Free PMC article.
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP; Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging Initiative. Shirzadi Z, et al. JAMA Neurol. 2023 Dec 1;80(12):1353-1363. doi: 10.1001/jamaneurol.2023.3618. JAMA Neurol. 2023. PMID: 37843849 Free PMC article.
8,928 results